Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Twelve Seas Investment Company (TWLVU)
Kensington Capital Acquisition (KCAC.U)
African Gold Acquisition (AGAC.U)
Fusion Acquisition II (FSNB.U)
Mcap Acquisition (MACQU)
Silverbox Engaged Merger I (SBEAU)
Ibere Pharmaceuticals (IBERU)
Freedom Acquisition I (FACT.U)
Arya Sciences Acquisition IV (ARYD)
Warrior Technologies Acquisition Company (WARR.U)
Austerlitz Acquisition Corporation II (ASZ.U)
Austerlitz Acquisition Corporation I (AUS.U)
Leo Holdings III Corp. (LIII.U)
Upcoming IPO
Property Solutions Acquisition II (PSAGU)
Nightdragon Acquisition (NDACU)
Roblox Corporation (RBLX)
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Neximmune, Inc. (NEXI)

Sector - Healthcare

Price chart

+53.29%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Their mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, they have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. They are evaluating two product candidates in clinical trials, NEXI-001 in patients with AML and NEXI-002 in patients with MM. They are actively dosing patients in both Phase I/II trials and expect to complete enrollment for both trials in 2021, with initial data on most patients in both trials expected by the end of 2021. As Phase I/II trials, the trials consist of two parts. In the first part of the trials, the initial safety evaluation phase, they will assess the safety and tolerability of NEXI-001 or NEXI-002 T cells. In the second part of the trials, the expansion phase, they will further define safety and will also evaluate the initial efficacy of each product candidate at the dose and regimen established in the safety evaluation phase. They are currently in the safety evaluation phase of both trials. Based on analysis of initial data, they also anticipate filing with the FDA to request Breakthrough Therapy Designation and regenerative medicine advanced therapy designation for both their NEXI-001 and NEXI-002 product candidates.
Industry
Pharmaceuticals
CEO CFO
Scott Carmer John Trainer
Employees Founded
44 2011

Contacts

Address: 9119 Gaither Road Gaithersburg, MD 20877

Telephone: (301) 825-9810

Web page: http://www.neximmune.com

IPO information

Expected Date 2/12/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4.7
Shares Revised (MM) 6.5
Expected offer amount (MM) $75.2
Realized offer amount(MM) $110.5

Financial Data (last reporting year)

Market Cap (MM) $316.32
Revenues (MM) $0
Net Income (Loss) (MM) $-26.9

Voting

What do you think will happen with the NEXI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Barclays

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Barclays/ Cantor/ Raymond James/ Allen & Co
CO-Managers
-

Sector: Healthcare

Tweets about $NEXI

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats